A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation

Clinical trial NCT04262388 · WITHDRAWN

Trial details

NCT number: NCT04262388
Sponsor: University Health Network, Toronto
Status: WITHDRAWN
Phase: Phase 2
Study type: INTERVENTIONAL

Pancreatic Ductal Adenocarcinoma Non-small Cell Lung Cancer Squamous Cell Carcinoma of Head and Neck

Start date: 2021-01-01
Primary completion: 2023-01-01
Enrollment: 0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.